Caxton Associates LP Exelixis, Inc. Transaction History
Caxton Associates LP
- $2.65 Billion
- Q3 2024
A detailed history of Caxton Associates LP transactions in Exelixis, Inc. stock. As of the latest transaction made, Caxton Associates LP holds 35,726 shares of EXEL stock, worth $1.21 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
35,726
Previous 72,953
51.03%
Holding current value
$1.21 Million
Previous $1.64 Million
43.44%
% of portfolio
0.03%
Previous 0.06%
Shares
9 transactions
Others Institutions Holding EXEL
# of Institutions
502Shares Held
243MCall Options Held
2.54MPut Options Held
2.29M-
Black Rock Inc. New York, NY33.5MShares$1.13 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.3MShares$991 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA25.4MShares$859 Million3.31% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.4MShares$519 Million0.63% of portfolio
-
State Street Corp Boston, MA11.4MShares$387 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $10.9B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...